Abstract:Recent studies showed that stereotactic ablative radiotherapy may provide survival benefit for cancer patients with a limited number of metastases lesions treated with curative intent. We hypothesized that stereotactic ablative radiotherapy is safe and effective in tumor control due to its ablative dose and high accuracy of irradiation. In this study we investigate the safety and efficacy of this treatment for patients with oligometastases from colorectal cancer (CRC). Forty-five histologically confirmed colorectal cancer patients were recruited from September 2017 to August 2019. The median age was 60 years and 12 patients were women. Each patient was treated with stereotactic ablative radiotherapy for one oligometastatic lesion unsuitable for resection or standard therapies. Among them 25 patients had lung metastasis, 12 had liver metastasis, 3 brain metastasis, 2 bone metastasis, 2 subcutaneously metastasis and 1 post peritoneal lymphatic nodes. Thirty-six (80%) patients had ≥1 systemic regimen before radiotherapy, and 17 (37.8%) patients had ≥2 regimens. The diameter of irradiated lesions ranges from 1 to 5.5cm. The prescribed doses were 32 to 40 Gy in 4 to 5 fractions to the brain lesions, 48 to 64 Gy in 6 to 8 fractions to the lung or liver lesions, 32 to 60 Gy in 4 to 10 fractions in other lesions, with modification according to the tolerance of the adjacent normal tissue. Biologically effective dose (BED) ranges from 57 to 132 Gy with a median of 86.4 Gy. The median follow-up period was 8 months (range, 2-21months). The 12-month and 18-month local control rates were 84.2% and 76.5%, respectively. In subgroups, the 12-month local control rates for BED ˂100 Gy and ≥100 Gy were 75% and 85% respectively. Local recurrence occurred in 5 patients (11.1%), among which 3 had KRAS mutant disease and 2 were of unknown KRAS status. Univariate analysis showed that there was no significant difference in local control rate based on BED value (˂100 Gy versus ≥100 Gy), KRAS status (mutant versus wild type) or metastatic tumor site (lung versus liver). The 6-month and 12-month PFS rate were 53.7% and 15.1% respectively and the median PFS was 7 months. There were no grade 3 or higher toxicities. Eight patients developed grade 2 acute toxicities including fatigue, cough and diarrhea; two patients developed grade 2 late toxicities including chronic cough and abdominal pain. This study showed that stereotactic ablative radiotherapy is well tolerated and effective for colorectal oligometastases. A prescription dose of BED ≥100 Gy should be considered if normal tissue constraints allow. Correlation of disease and treatment characteristics with local control needed to be investigated with larger cohort. Further homogenous cohort would better evaluate long term benefit of stereotactic ablative radiotherapy for patients with oligometastatic CRC.

[Stereotactic body radiation therapy for patients with lung and liver oligometastases from colorectal cancer: a phase Ⅱ trial].

Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients with Lung Oligometastases or Oligoprogression from Colorectal Cancer

Stereotactic body radiotherapy prolongs the progression-free survival and delays the change of systemic therapy regimen in patients with lung oligoprogressive metastatic colorectal cancer

Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer

Efficacy and Safety Outcomes of Using Stereotactic Ablative Radiotherapy for Oligometastatic Lesions from Colorectal Cancer

110P Analysis for Stereotactic Body Radiotherapy (SBRT) Effect for Colorectal Liver Metastases

Stereotactic body radiation therapy in non-liver colorectal metastases: a scoping review

Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma.

Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer

Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes

Multi-institutional analysis of extracranial oligometastatic colorectal cancer patients treated with stereotactic body radiation therapy: TROD 02-008 study

Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions

Stereotactic body radiation therapy for colorectal cancer liver metastases

Stereotactic Body Radiotherapy Combined with Sintilimab in Patients with Recurrent or Oligometastatic Hepatocellular Carcinoma: A Phase II Clinical Trial.

A phase II study of stereotactic body radiotherapy (SBRT) combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma (HCC).

Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro/eortc consensus recommendations

Whole-Brain Radiotherapy Combined with Anlotinib for Multiple Brain Metastases from Non-small Cell Lung Cancer Without Targetable Driver Mutation: A Single-Arm, Phase II Study

Stereotactic Body Radiation Therapy Using the CyberKnife® System for Patients with Liver Metastases

Clinical Outcomes and Prognostic Factors of Salvage Stereotactic Body Radiotherapy for Post-Surgical Thoracic Oligo-Recurrence/Metastasis of Non-Small-Cell Lung Cancer

MR-guided online adaptive stereotactic body radiotherapy (MRgSBRT) of primary lung tumors and lung oligometastases

Stereotactic radiotherapy for pulmonary oligometastases: a systematic review